The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
In this Phase III study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous XW003 injection or placebo, including a dose-escalation period, for up to 48 weeks
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
140
subcutaneous injection
subcutaneous injection
Rui Jin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGChange from baseline in Apnea-Hypopnea Index (AHI)
Time frame: at week 48
Percent Change From Baseline in AHI
Time frame: at week 48
Percentage of Participants With ≥50% AHI Reduction From Baseline
Time frame: at week 48
Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10
Time frame: at week 48
Percent Change From Baseline in body weight
Time frame: at week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.